文献速递妇科

参加组织性筛查项目的HPV持续感染女性的阴道镜与组织病理学评估

Colposcopic and histopathologic evaluation of women with HPV persistence exiting an organized screening program.
PubMed 文献 · Am J Obstet Gynecol · 2019-10-01

在瑞典56-60岁女性中开展随机健康政策,HPV阳性/细胞学阴性者1年或3年后复查;持续感染者行阴道镜。1年组持续阳性率52%高于3年组40%(P=.042),CIN2+检出率1年组23%、3年组20%,两组均无宫颈癌。作者认为3年后复查安全。

要点

  • HPV阳性/细胞学阴性女性1年复查持续阳性率52%高于3年复查40%(P=.042)。
  • 阴道镜下CIN2+检出率1年组23%(19/82)、3年组20%(9/45),两组均未发现宫颈癌。
  • HPV16是持续感染最常见基因型,1年组占18%、3年组占20%。

核心结论

  • 在参加组织性宫颈筛查的绝经后女性中,将HPV复查推迟3年是安全的。
  • 随访时CIN2+风险较高,HPV基因分型以及无可见阴道镜病变时行宫颈管取样和随机活检均有值得注意的检出。

研究设计与样本

  • 随机健康政策:2012年1月至2014年5月在瑞典斯德哥尔摩/哥特兰地区向50%的56-60岁常住女性提供HPV筛查。
  • 基线HPV阳性/细胞学阴性者转诊复查,1年组176人、3年组137人;持续感染者行阴道镜包括活检和宫颈管取样。

主要发现

  • HPV患病率5.5%(7325名参检者中405人)。
  • 1年后176人中91人(52%)持续HPV阳性,3年后137人中55人(40%)持续阳性(P=.042)。
  • 复查细胞学阳性:1年组91人中10人(12%),3年组55人中15人(33%)(P=.005)。
  • 阴道镜参会率相似:1年组91人中82人(90%),3年组55人中45人(82%)。
  • 组织学确诊CIN2+:1年组82人中19人(23%),3年组45人中9人(20%);登记随访两组均无宫颈癌。

关键数值与推荐

  • 宫颈管取样对CIN2+的阳性预测值为43-50%,点活检为28-31%。
  • 所有行阴道镜的女性均为绝经后。

临床怎么用

  • 作者认为在参加组织性筛查的绝经后女性中将HPV复查推迟3年是安全的。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Human papillomavirus-based screening has a higher sensitivity for precursors of cervical cancer compared with cytology-based screening. However, more evidence is needed on optimal management of human papillomavirus-positive women. OBJECTIVE: The objective of the study was to compare the risk of histopathologically confirmed cervical intraepithelial lesions grade 2 or worse after 1 and 3 years of human papillomavirus persistence, respectively, and evaluate the clinical management of human papillomavirus-positive women in the 56-60 year age group. STUDY DESIGN: This was a randomized health care policy offering human papillomavirus screening to 50% of resident women aged 56-60 years in the Stockholm/Gotland region of Sweden during January 2012 through May 2014. Women who were human papillomavirus positive/cytology negative at baseline were referred for a repeat test after 1 or 3 years. In case of human papillomavirus persistence, women were referred for colposcopy, including biopsies and endocervical sampling. RESULTS: The human papillomavirus prevalence was 5.5% (405 women of 7325 attending). Among the 405 human papillomavirus-positive women, 313 were reflex test cytology negative at baseline and were referred for a repeat human papillomavirus test, 176 women after 1 year and 137 women after 3 years. After 1 year, 91 of 176 (52%) were persistently human papillomavirus positive and after 3 years 55 of 137 (40%) (P = .042). In repeat cytology, 10 of the 91 (12%) were positive after 1 year and 15 of 55 (33%) after 3 years (P = .005). The attendance rates for colposcopy were similar: 82 of 91 (90%) in the 1 year group and 45 of 55 (82%) in the 3 year group. All women attending colposcopy were postmenopausal, and endocervical sampling and punch biopsies were performed to facilitate colposcopic management, with a positive predictive value of 43-50% and 28-31%, respectively. Histopathologically confirmed cervical intraepithelial lesions grade 2 or worse was found in 19 of 82 women (23%) and 9 of 45 women (20%) in the 1 year and 3 year groups, respectively, and registry linkage follow-up found no cancers in either group. Human papillomavirus genotyping was predictive of cervical intraepithelial lesions grade 2 or worse, and human papillomavirus 16 was the most common genotype at human papillomavirus persistence, occurring in 18% of the cases in the 1 year group and 20% in the 3 year group. CONCLUSION: It was safe to postpone repeat human papillomavirus tests for 3 years in postmenopausal women attending the organized cervical screening program. There was a high risk for cervical intraepithelial lesions grade 2 or worse at follow-up and noteworthy yields from human papillomavirus genotyping as well as endocervical sampling and random biopsies in the absence of visible colposcopic lesions.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Sahlgren H, Elfström KM, Lamin H, et al. Colposcopic and histopathologic evaluation of women with HPV persistence exiting an organized screening program. Am J Obstet Gynecol. 2019. PMID: 31585095. doi:10.1016/j.ajog.2019.09.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。